Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients

Prostate Cancer Clinical Trial

Official title:

Phase 1b Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03465345
• Other study ID #: 102797
• Status: Withdrawn
• Phase: Phase 1
• Start date: July 11, 2018
• Est. completion date: July 11, 2018

Study information

• Verified date: August 2018
• Source: Medical University of South Carolina
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall goal of this study is to identify a safe dose of metformin, in combination with oligomeric procyanidin complex (OPC) for pharmacologic reduction of AGE levels in patients with prostate cancer.

Description:

AGEs (advanced glycation endpoints) are a type of metabolite, or substance, found in the food. The AGE content in food is determined by the types of food you eat and also how you prepare your food. The researchers helping conduct this study have found a potential link between AGE levels and cancer. The purpose of this study is to identify safe pharmaceutical agents that can reduce the AGE levels in subjects with advanced cancer.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 11, 2018
• Est. primary completion date: July 11, 2018
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Confirmation of adenocarcinoma of the prostate that is documented by one of the following: pathology report or clinic note with documented history of prostate cancer.

2. Subjects must be receiving ADT with a GnRH agonist or antagonist, with or without an anti-androgen, with a current testosterone level documented to be <50ng/dL at enrollment. Subjects whose ADT is interrupted may enroll or continue on study as long as the testosterone is documented to remain <50ng/dL for the entire duration of study participation. Subjects who have undergone orchiectomy are also eligible.

3. Subjects must have adequate hematologic, renal, and hepatic function at baseline, as follows:

• Hematology parameters: ANC >1000/mcL, platelets > 100,000/mcL, Hgb >8.0gm/dL

• Renal Function: eGFR of = 45mls/min using Cockkroft and Gault formula (see appendix C).

• Liver Function: Total bilirubin =ULN, AST and ALT <1.5xULN, Prior radiation therapy allowed

4. Subjects may have diabetes mellitus but must not be taking metformin.

5. Able to swallow and retain oral medication

6. ECOG performance status of 0 - 2

7. Ability to sign written informed consent

8. Testosterone level <50ng/dL at time of enrollment.

9. Age 18 or older.

Exclusion Criteria:

1. Known allergy to grapes or grape seed

2. Known hypersensitivity or intolerance to metformin.

3. Any condition associated with increased risk of metformin-associated lactic acidosis (e.g. congestive heart failure defined as NYHA Class III or IV functional status, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day).

4. Prior cytotoxic chemotherapy for metastatic prostate cancer; prior treatment with genomically-targeted agents, or Provenge is allowed.

5. History of receiving more than 2 classes of ADT.

6. Current use of metformin, or strong antioxidants (extracts from grape seed, milk thistle; pine bark, green tea, saw palmetto; resveratrol; flavonoids; catechins; ellagic acid), large quantities of red grapes, white button mushrooms, red wine

7. PSA doubling time of <6 months, measured over the 3 months prior to enrollment.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Metformin
Metformin: The starting dose for Metformin is 850mg once a day, the second dose is 850mg once a day; the third dose level is 850mg twice a day; the fourth dose level is 850mg twice a day. Each dose level lasts for 28 days.
• Oligomeric Procyanidin Complex
OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.

Locations

Country	Name	City	State
United States	Medical University of South Carolina	Charleston	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD) of metformin in combination with OPC in PCa subjects.		112 days
Secondary	Correlation between changes to AGE level and changes to PSA.		112 days
Secondary	Correlation between changes to AGE level and changes to BMI.		112 days
Secondary	Correlation between changes to AGE level and changes to insulin resistance.		112 days
Secondary	Correlation between changes to AGE level and changes to A1C.		112 days
Secondary	Correlations between changes to AGE level and changes to testosterone.		112 days
Secondary	Correlation between changes to AGE level and changes to diet.		112 days
Secondary	Correlation between changes to AGE level and changes to quality of life.	FACT-P and AUA questionnaires	112 days
Secondary	Frequency of adverse events as assessed by CTCAE v. 4	Toxicities will be tabulated by type and grade and the proportion of patients with grade 3, grade 4 or an SAE will be estimated with a 90% confidence interval.	112 days
Secondary	Correlation between AGE levels and sRAGE (soluble receptor for AGE) expression and signaling.		112 days
Secondary	Correlation between changes to AGE level and OPC metabolite levels.		112 days
Secondary	Correlation between changes to AGE level and changes in the stool. microbiome.		112 days